With over 2000+ studies conducted between two clinical sites in Toronto, Canada and St. Louis, USA, BioPharma has built a brand of excellence in the conduct of Bioequivalence (BE) and bioavailability (BA) studies to support both generic and hybrid drug filings and 505(b)(2) New Drug Applications.
With impeccable quality and reputable data in mind, the BioPharma team is trained and empowered to deliver its very best each and every day. This attention to detail is supported by numerous successful Regulatory Inspections from the US FDA, EMA, UK MHRA, ANVISA, and Health Canada. With our in-house scientific and regulatory expertise, proficient in all major drug markets, BioPharma can support the full study conduct from study design and protocol inception to the issuance of the final Clinical Study Report.